financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 11, 2025 7:43 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

First Trust Advisors L.P.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

NCC Group plc ( NCCGF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10/11/25

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES / NO / N/A

If YES, specify which: NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

 

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,688,581

 

 

 

4.98%

 

 

(2) Cash-settled derivatives:

 

N/A

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

 

 

 

 

TOTAL:

15,688,581

4.98%

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

1p Ordinary Shares

 

 

Purchase

4642

146

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

N/A

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

none

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

 

 

(c) Attachments

Class of relevant security:

 

 

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,688,581

 

 

 

4.98%

 

 

(2) Cash-settled derivatives:

 

N/A

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

 

 

 

 

TOTAL:

15,688,581

4.98%

 

 

0

Class of relevant security:

 

 

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,688,581

 

 

 

4.98%

 

 

(2) Cash-settled derivatives:

 

N/A

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

 

 

 

 

TOTAL:

15,688,581

4.98%

 

 

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: First Trust Portfolios

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US senator challenges defense industry on right-to-repair opposition as funding talks continue
US senator challenges defense industry on right-to-repair opposition as funding talks continue
Nov 10, 2025
WASHINGTON (Reuters) -Democratic U.S. Senator Elizabeth Warren is escalating pressure on the defense industry to stop opposing military right-to-repair legislation, as House and Senate negotiators work to finalize the fiscal 2026 National Defense Authorization Act. In a sharply-worded November 5 letter to the National Defense Industrial Association (NDIA) obtained by Reuters, Warren accused the industry group of attempting to undermine...
Canada's K92 Mining Q3 net income rises 84%
Canada's K92 Mining Q3 net income rises 84%
Nov 10, 2025
Overview * K92 Q3 revenue rises 45% yr/yr to record $177.5 mln * Net income for Q3 increases 84% yr/yr to $85.7 mln * Company completes Stage 3 Expansion Process Plant under budget Outlook * K92 Mining ( KNTNF ) on track to meet 2025 production guidance of 160,000-185,000 oz AuEq * Stage 3 Expansion commissioning on schedule for November...
ARS Pharmaceuticals' Q3 loss widens on higher costs
ARS Pharmaceuticals' Q3 loss widens on higher costs
Nov 10, 2025
Overview * ARS Pharmaceuticals Q3 2025 revenue at $32.5 mln, driven by neffy U.S. sales * Net loss for Q3 2025 was $51.2 mln, reflecting high SG&A expenses * Company holds $288.2 mln in cash and investments, funding operations to cash-flow break-even Outlook * Company expects unrestricted payor access with gross-to-net retention of at least 50% * ARS Pharma anticipates...
CBAK Energy Q3 revenue rises, boosted by battery raw materials segment
CBAK Energy Q3 revenue rises, boosted by battery raw materials segment
Nov 10, 2025
Overview * CBAK Energy ( CBAT ) Q3 revenue grows 36.5% yr/yr, driven by battery raw materials segment * Net income for Q3 increases significantly, driven by battery business profitability * Company faces declining gross margin and operating loss due to product transition Outlook * CBAK Energy ( CBAT ) expects growth from new production lines starting mid-November * Company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved